Overview

A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors

Status:
RECRUITING
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
This study is an open-label, multicenter, dose-escalation and cohort expansion phase I clinical study to evaluate the safety, tolerability, pharmacokinetics characteristics or preliminary efficacy and antitumor activity in patients with locally advanced or metastatic breast cancer and other solid tumors.
Phase:
PHASE1
Details
Lead Sponsor:
Sichuan Baili Pharmaceutical Co., Ltd.
Collaborator:
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.